These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

696 related articles for article (PubMed ID: 25590800)

  • 1. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).
    Leverson JD; Zhang H; Chen J; Tahir SK; Phillips DC; Xue J; Nimmer P; Jin S; Smith M; Xiao Y; Kovar P; Tanaka A; Bruncko M; Sheppard GS; Wang L; Gierke S; Kategaya L; Anderson DJ; Wong C; Eastham-Anderson J; Ludlam MJ; Sampath D; Fairbrother WJ; Wertz I; Rosenberg SH; Tse C; Elmore SW; Souers AJ
    Cell Death Dis; 2015 Jan; 6(1):e1590. PubMed ID: 25590800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival.
    Eichhorn JM; Alford SE; Sakurikar N; Chambers TC
    Exp Cell Res; 2014 Apr; 322(2):415-24. PubMed ID: 24556425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.
    Faber AC; Farago AF; Costa C; Dastur A; Gomez-Caraballo M; Robbins R; Wagner BL; Rideout WM; Jakubik CT; Ham J; Edelman EJ; Ebi H; Yeo AT; Hata AN; Song Y; Patel NU; March RJ; Tam AT; Milano RJ; Boisvert JL; Hicks MA; Elmiligy S; Malstrom SE; Rivera MN; Harada H; Windle BE; Ramaswamy S; Benes CH; Jacks T; Engelman JA
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1288-96. PubMed ID: 25737542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression.
    Woo SM; Min KJ; Seo BR; Nam JO; Choi KS; Yoo YH; Kwon TK
    Cell Death Dis; 2014 Nov; 5(11):e1514. PubMed ID: 25375379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
    Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.
    Goodwin CM; Rossanese OW; Olejniczak ET; Fesik SW
    Cell Death Differ; 2015 Dec; 22(12):2098-106. PubMed ID: 26045046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.
    Choudhary GS; Al-Harbi S; Mazumder S; Hill BT; Smith MR; Bodo J; Hsi ED; Almasan A
    Cell Death Dis; 2015 Jan; 6(1):e1593. PubMed ID: 25590803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
    Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
    Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL.
    Shi J; Zhou Y; Huang HC; Mitchison TJ
    Cancer Res; 2011 Jul; 71(13):4518-26. PubMed ID: 21546570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax.
    Kour S; Rana S; Contreras JI; King HM; Robb CM; Sonawane YA; Bendjennat M; Crawford AJ; Barger CJ; Kizhake S; Luo X; Hollingsworth MA; Natarajan A
    Mol Pharmacol; 2019 Oct; 96(4):419-429. PubMed ID: 31467029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor.
    Xiao Y; Nimmer P; Sheppard GS; Bruncko M; Hessler P; Lu X; Roberts-Rapp L; Pappano WN; Elmore SW; Souers AJ; Leverson JD; Phillips DC
    Mol Cancer Ther; 2015 Aug; 14(8):1837-47. PubMed ID: 26013319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia.
    Besbes S; Pocard M; Mirshahi M; Billard C
    Crit Rev Oncol Hematol; 2016 Apr; 100():32-6. PubMed ID: 26899021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
    Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
    Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.
    Lheureux S; N'Diaye M; Blanc-Fournier C; Dugué AE; Clarisse B; Dutoit S; Giffard F; Abeilard E; Briand M; Labiche A; Grellard JM; Crouet H; Martin S; Joly F; Poulain L
    Int J Cancer; 2015 Mar; 136(5):E340-50. PubMed ID: 25066666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.
    Tahir SK; Yang X; Anderson MG; Morgan-Lappe SE; Sarthy AV; Chen J; Warner RB; Ng SC; Fesik SW; Elmore SW; Rosenberg SH; Tse C
    Cancer Res; 2007 Feb; 67(3):1176-83. PubMed ID: 17283153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
    Jebahi A; Villedieu M; Pétigny-Lechartier C; Brotin E; Louis MH; Abeilard E; Giffard F; Guercio M; Briand M; Gauduchon P; Lheureux S; Poulain L
    Cancer Lett; 2014 Jun; 348(1-2):38-49. PubMed ID: 24650799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obatoclax is a direct and potent antagonist of membrane-restricted Mcl-1 and is synthetic lethal with treatment that induces Bim.
    Nguyen M; Cencic R; Ertel F; Bernier C; Pelletier J; Roulston A; Silvius JR; Shore GC
    BMC Cancer; 2015 Aug; 15():568. PubMed ID: 26231047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of synergy of BH3 mimetics and paclitaxel in chronic myeloid leukemia cells: Mcl-1 inhibition.
    Song T; Chai G; Liu Y; Xie M; Chen Q; Yu X; Sheng H; Zhang Z
    Eur J Pharm Sci; 2015 Apr; 70():64-71. PubMed ID: 25596561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.
    Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z
    Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines.
    Lian BSX; Yek AEH; Shuvas H; Abdul Rahman SF; Muniandy K; Mohana-Kumaran N
    BMC Res Notes; 2018 Mar; 11(1):197. PubMed ID: 29580266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.